Works by Fineman, Mark S.

Results: 16

First‐in‐human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 9, p. 2447, doi. 10.1111/dom.15066

By:

Fineman, Mark S.;
Bryant, Christine L. N.;
Colbert, Kevin;
Jozefiak, Thomas H.;
Petersen, John S.;
Horowitz, Michael;
Vora, Jiten;
Rayner, Christopher K.;
Wabnitz, Paul;
Nimgaonkar, Ashish

Publication type:

Article

Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes.

Published in:

Diabetes Care, 2005, v. 28, n. 5, p. 1092, doi. 10.2337/diacare.28.5.1092

By:

DeFronzo, Ralph A.;
Ratner, Robert E.;
Han, Jenny;
Kim, Dennis D.;
Fineman, Mark S.;
Baron, Alain D.

Publication type:

Article

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea.

Published in:

Diabetes Care, 2005, v. 28, n. 5, p. 1083, doi. 10.2337/diacare.28.5.1083

By:

Kendall, David M.;
Riddle, Matthew C.;
Rosenstock, Julio;
Zhuang, Dongliang;
Kim, Dennis D.;
Fineman, Mark S.;
Baron, Alain D.

Publication type:

Article

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

Published in:

2004

By:

Buse, John B.;
Henry, Robert R.;
Han, Jenny;
Kim, Dennis D.;
Fineman, Mark S.;
Baron, Alain D.;
Exenatide-113 Clinical Study Group

Publication type:

journal article

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

Published in:

2003

By:

Fineman, Mark S.;
Bicsak, Thomas A.;
Shen, Larry Z.;
Taylor, Kristin;
Gaines, Eling;
Varns, Amanda;
Kim, Dennis;
Baron, Alain O.;
Baron, Alain D

Publication type:

journal article

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

Published in:

2003

By:

Hollander, Priscilla A.;
Levy, Philip;
Fineman, Mark S.;
Maggs, David G.;
Shen, Larry Z.;
Strobel, Susan A.;
Weyer, Christian;
Kolterman, Orville G.

Publication type:

journal article

Gestational diabetes mellitus is associated with an increase in the total concentration of amylin molecules.

Published in:

1998

By:

Wareham, Nicholas J.;
Swinn, Robert;
Fineman, Mark S.;
Koda, Joy E.;
Taylor, Kevin;
Williams, Desmond E. M.;
O'Rahilly, Stephen;
Wareham, N J;
Swinn, R;
Fineman, M S;
Koda, J E;
Taylor, K;
Williams, D E;
Rahilly, S O

Publication type:

research

Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes.

Published in:

Journal of Clinical Endocrinology & Metabolism, 2005, v. 90, n. 11, p. 5991, doi. 10.1210/jc.2005-1093

By:

Fehse, Frauke;
Trautmann, Michael;
Holst, Jens J.;
Halseth, Amy E.;
Nanayakkara, Nuwan;
Nielsen, Loretta L.;
Fineman, Mark S.;
Kim, Dennis D.;
Nauck, Michael A.

Publication type:

Article

Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes.

Published in:

Journal of Clinical Endocrinology & Metabolism, 2003, v. 88, n. 7, p. 3082, doi. 10.1210/jc.2002-021545

By:

KOLTERMAN, ORVILLE G.;
BUSE, JOHN B.;
FINEMAN, MARK S.;
GAINES, ELING;
HEINTZ, SONJA;
BICSAK, THOMAS A.;
TAYLOR, KRISTIN;
KIM, DENNIS;
AISPORNA, MARIA;
YAN WANG;
BARON, ALAIN D.

Publication type:

Article

Properties of pramlintide and insulin upon mixing.

Published in:

American Journal of Health-System Pharmacy, 2005, v. 62, n. 8, p. 816, doi. 10.1093/ajhp/62.8.816

By:

Weyer, Christian;
Fineman, Mark S.;
Strobel, Susan;
Shen, Larry;
Data, Joann;
Kolterman, Orville G.;
Sylvestri, Mario F.

Publication type:

Article

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

Published in:

American Journal of Health-System Pharmacy, 2005, v. 62, n. 2, p. 173., doi. 10.1093/ajhp/62.2.173

By:

Kolterman, Orville G.;
Kim, Dennis D.;
Shen, Larry;
Ruggles, James A.;
Nielsen, Loretta L.;
Fineman, Mark S.;
Baron, Alain D.

Publication type:

Article

Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: a placebo-controlled study.

Published in:

European Journal of Endocrinology, 2000, v. 143, n. 5, p. 593

By:

Jùrgensen, Jens O. L.;
Rosenfalck, Anne M.;
Fisker, Sanne;
Nyholm, Birgit;
Fineman, Mark S.;
Schmitz, Ole;
Madsbad, Sten;
Holst, Jens J.;
Christiansen, Jens S.

Publication type:

Article

Spinal Disinhibition in Experimental and Clinical Painful Diabetic Neuropathy.

Published in:

2017

By:

Marshall, Andrew G.;
Lee-Kubli, Corinne;
Azmi, Shazli;
Zhang, Michael;
Ferdousi, Maryam;
Mixcoatl-Zecuatl, Teresa;
Petropoulos, Ioannis N.;
Ponirakis, Georgios;
Fineman, Mark S.;
Fadavi, Hassan;
Frizzi, Katie;
Tavakoli, Mitra;
Jeziorska, Maria;
Jolivalt, Corinne G.;
Boulton, Andrew J. M.;
aEfron, Nathan;
Calcutt, Nigel A.;
Malik, Rayaz A.;
Efron, Nathan

Publication type:

journal article

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.

Published in:

Diabetes/Metabolism Research & Reviews, 2004, v. 20, n. 5, p. 411, doi. 10.1002/dmrr.499

By:

Fineman, Mark S.;
Shen, Larry Z.;
Taylor, Kristin;
Kim, Dennis D.;
Baron, Alain D.

Publication type:

Article

Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times Relative to Subcutaneous Injection of Pramlintide in Subjects With Type 2 Diabetes.

Published in:

Journal of Clinical Pharmacology, 2007, v. 47, n. 7, p. 798, doi. 10.1177/0091270007300949

By:

Kellmeyer, Terrie A.;
Kesty, Nicole C.;
Yan Wang;
Frias, Juan P.;
Fineman, Mark S.

Publication type:

Article

Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study.

Published in:

Rheumatology & Therapy, 2023, v. 10, n. 6, p. 1741, doi. 10.1007/s40744-023-00604-7

By:

Fineman, Mark S.;
McAlindon, Timothy E.;
Lattermann, Christian;
Swearingen, Christopher J.;
Kennedy, Sarah;
Lopez, Victor A.;
Simsek, Ismail;
Tambiah, Jeyanesh R. S.;
Yazici, Yusuf

Publication type:

Article